10-QPeriod: Q2 FY2005

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2005

Filed August 5, 2005For Securities:EW

Summary

Edwards Lifesciences Corporation reported solid revenue growth for the second quarter and first half of 2005, driven primarily by its Heart Valve Therapy segment, with the Carpentier-Edwards PERIMOUNT Magna valve showing strong performance. Total net sales increased by 10.1% for the quarter and 8.0% for the first half, demonstrating continued demand for its cardiovascular products. The company also saw improvements in gross profit margin, indicating effective cost management and favorable product mix. However, the company is navigating some regulatory delays in its percutaneous heart valve programs, which are expected to push CE mark approval back by three to six months, though management does not anticipate a material financial impact in 2005. Overall, the results suggest ongoing operational strength and market leadership in key cardiovascular areas.

Key Highlights

  • 1Net sales increased by 10.1% to $258.2 million for the three months ended June 30, 2005, and by 8.0% to $507.3 million for the six months ended June 30, 2005.
  • 2Heart Valve Therapy segment sales grew by 17.3% for the quarter and 13.7% for the first half, largely driven by the Carpentier-Edwards PERIMOUNT Magna valve.
  • 3Gross profit margin improved to 62.1% for the quarter and 61.7% for the six-month period, up from 60.6% and 59.3%, respectively, in the prior year.
  • 4Research and development expenses increased due to investments in percutaneous heart valve programs.
  • 5The company experienced delays in its percutaneous aortic heart valve clinical feasibility trials in the U.S. and Europe, attributed to awaiting FDA approval for a new delivery system.
  • 6Special charges totaling $22.8 million were recorded in June 2005 related to restructuring development and supply agreements for percutaneous heart valves, and $4.8 million for impairment of investments.
  • 7Cash and cash equivalents increased significantly to $96.1 million as of June 30, 2005, from $48.9 million at the end of 2004, indicating improved liquidity.

Frequently Asked Questions

Revenue growth was primarily driven by the Heart Valve Therapy segment, particularly sales of the Carpentier-Edwards PERIMOUNT Magna valve, which saw increased market share globally. The Critical Care and Vascular segments also contributed positively, with some benefit from foreign currency exchange rate fluctuations.

Yes, the company is facing delays in its percutaneous aortic heart valve clinical feasibility trials in the U.S. and Europe due to awaiting FDA approval for a new retrograde delivery system. This is expected to postpone CE mark approval by three to six months, although management does not foresee a material financial impact in 2005.

Gross profit margin improved due to sales of higher-margin heart valve products and favorable impacts from foreign currency. While Selling, General, and Administrative (SG&A) expenses increased due to higher sales and marketing costs and international expenses, and Research & Development (R&D) expenses rose with investments in percutaneous heart valve programs, the overall profitability shows improvement, particularly in gross margin.

The company's liquidity has improved, with cash and cash equivalents increasing to $96.1 million as of June 30, 2005, from $48.9 million at the end of 2004. They also have access to a $500 million revolving credit facility and securitization programs.